{
  "guideline": {
    "id": "PA166288201",
    "name": "Annotation of CPIC Guideline for venlafaxine and CYP2D6",
    "source": "CPIC",
    "version": 2,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166288201",
    "relatedChemicals": [
      {
        "id": "PA451866",
        "name": "venlafaxine",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA128",
        "name": "cytochrome P450 family 2 subfamily D member 6",
        "symbol": "CYP2D6"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166300949",
      "name": "Recommendation PA166300949",
      "population": "general",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451866",
          "name": "venlafaxine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093929,
        "html": "<p>No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.</p>\n"
      },
      "implications": [
        "CYP2D6: Increased metabolism of venlafaxine to the active metabolite O-desmethylvenlafaxine (desvenlafaxine) and increased O-desmethylvenlafaxine:venlafaxine ratio as compared to CYP2D6 normal metabolizers. There is insufficient evidence supporting the clinical impact of increased O-desmethylvenlafaxine:venlafaxine ratio in CYP2D6 ultrarapid metabolizers."
      ],
      "lookupKey": {
        "CYP2D6": "≥4.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300958",
      "name": "Recommendation PA166300958",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA451866",
          "name": "venlafaxine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093938,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n"
      },
      "implications": [
        "CYP2D6: Normal metabolism"
      ],
      "lookupKey": {
        "CYP2D6": "2.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300953",
      "name": "Recommendation PA166300953",
      "population": "general",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451866",
          "name": "venlafaxine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093933,
        "html": "<p>No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.</p>\n"
      },
      "implications": [
        "CYP2D6: Increased metabolism of venlafaxine to the active metabolite O-desmethylvenlafaxine (desvenlafaxine) and increased O-desmethylvenlafaxine:venlafaxine ratio as compared to CYP2D6 normal metabolizers. There is insufficient evidence supporting the clinical impact of increased O-desmethylvenlafaxine:venlafaxine ratio in CYP2D6 ultrarapid metabolizers."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300966",
      "name": "Recommendation PA166300966",
      "population": "general",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451866",
          "name": "venlafaxine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093946,
        "html": "<p>No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.</p>\n"
      },
      "implications": [
        "CYP2D6: Decreased metabolism of venlafaxine to active metabolite O-desmethylvenlafaxine (desvenlafaxine) and decreased O-desmethylvenlafaxine:venlafaxine ratio as compared to normal metabolizers. There is insufficient evidence supporting the clinical impact of the decreased O-desmethylvenlafaxine:venlafaxine ratio in CYP2D6 intermediate metabolizers."
      ],
      "lookupKey": {
        "CYP2D6": "0.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300962",
      "name": "Recommendation PA166300962",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA451866",
          "name": "venlafaxine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093942,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n"
      },
      "implications": [
        "CYP2D6: Normal metabolism"
      ],
      "lookupKey": {
        "CYP2D6": "1.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300959",
      "name": "Recommendation PA166300959",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA451866",
          "name": "venlafaxine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093939,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n"
      },
      "implications": [
        "CYP2D6: Normal metabolism"
      ],
      "lookupKey": {
        "CYP2D6": "2.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300967",
      "name": "Recommendation PA166300967",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA451866",
          "name": "venlafaxine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093947,
        "html": "<p>Consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2D6.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when adjusting dose or selecting an alternative therapy.</p>\n"
      },
      "implications": [
        "CYP2D6: Decreased metabolism of venlafaxine to the active metabolite O-desmethylvenlafaxine (desvenlafaxine) and greatly decreased O-desmethylvenlafaxine:venlafaxine ratio as compared to CYP2D6 normal and intermediate metabolizers. The clinical impact of increased venlafaxine and decreased O-desmethylvenlafaxine:venlafaxine ratio in CYP2D6 poor metabolizers is unclear, but CYP2D6 PM genotype has been associated with adverse effects."
      ],
      "lookupKey": {
        "CYP2D6": "0.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300954",
      "name": "Recommendation PA166300954",
      "population": "general",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451866",
          "name": "venlafaxine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093934,
        "html": "<p>No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.</p>\n"
      },
      "implications": [
        "CYP2D6: Increased metabolism of venlafaxine to the active metabolite O-desmethylvenlafaxine (desvenlafaxine) and increased O-desmethylvenlafaxine:venlafaxine ratio as compared to CYP2D6 normal metabolizers. There is insufficient evidence supporting the clinical impact of increased O-desmethylvenlafaxine:venlafaxine ratio in CYP2D6 ultrarapid metabolizers."
      ],
      "lookupKey": {
        "CYP2D6": "4.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300963",
      "name": "Recommendation PA166300963",
      "population": "general",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451866",
          "name": "venlafaxine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093943,
        "html": "<p>No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.</p>\n"
      },
      "implications": [
        "CYP2D6: Decreased metabolism of venlafaxine to active metabolite O-desmethylvenlafaxine (desvenlafaxine) and decreased O-desmethylvenlafaxine:venlafaxine ratio as compared to normal metabolizers. There is insufficient evidence supporting the clinical impact of the decreased O-desmethylvenlafaxine:venlafaxine ratio in CYP2D6 intermediate metabolizers."
      ],
      "lookupKey": {
        "CYP2D6": "1.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300950",
      "name": "Recommendation PA166300950",
      "population": "general",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451866",
          "name": "venlafaxine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093930,
        "html": "<p>No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.</p>\n"
      },
      "implications": [
        "CYP2D6: Increased metabolism of venlafaxine to the active metabolite O-desmethylvenlafaxine (desvenlafaxine) and increased O-desmethylvenlafaxine:venlafaxine ratio as compared to CYP2D6 normal metabolizers. There is insufficient evidence supporting the clinical impact of increased O-desmethylvenlafaxine:venlafaxine ratio in CYP2D6 ultrarapid metabolizers."
      ],
      "lookupKey": {
        "CYP2D6": "≥6.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300947",
      "name": "Recommendation PA166300947",
      "population": "general",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451866",
          "name": "venlafaxine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093927,
        "html": "<p>No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.</p>\n"
      },
      "implications": [
        "CYP2D6: Increased metabolism of venlafaxine to the active metabolite O-desmethylvenlafaxine (desvenlafaxine) and increased O-desmethylvenlafaxine:venlafaxine ratio as compared to CYP2D6 normal metabolizers. There is insufficient evidence supporting the clinical impact of increased O-desmethylvenlafaxine:venlafaxine ratio in CYP2D6 ultrarapid metabolizers."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166301331",
      "name": "Recommendation Annotation PA166301331",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA451866",
          "name": "venlafaxine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452095650,
        "html": "<p>xN is not a valid input for CYP2D6 copy number alleles. Please select a copy number representation as outlined below.</p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>xN Allele</th>\n<th>Possible selection</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>*1xN</td>\n<td>*1x2 or *1x≥3</td>\n</tr>\n<tr>\n<td>*2xN</td>\n<td>*2x2 or *2x≥3</td>\n</tr>\n<tr>\n<td>*3xN</td>\n<td>*3x2</td>\n</tr>\n<tr>\n<td>*4xN</td>\n<td>*4x2 or *4x≥3</td>\n</tr>\n<tr>\n<td>*6xN</td>\n<td>*6x2</td>\n</tr>\n<tr>\n<td>*35xN</td>\n<td>*35x2</td>\n</tr>\n<tr>\n<td>*36xN</td>\n<td>*36x2</td>\n</tr>\n<tr>\n<td>*43xN</td>\n<td>*43x2</td>\n</tr>\n<tr>\n<td>*45xN</td>\n<td>*45x2</td>\n</tr>\n</tbody>\n</table>\n<ul>\n<li>For normal function alleles (*1 and *2) selecting <strong>*1x2 versus *1x≥3</strong> or <strong>*2x2 versus *2x≥3</strong> will affect the resulting CYP2D6 phenotype.</li>\n<li>CPIC CYP2D6 ultrarapid metabolizer phenotype is assigned an activity score (AS) of &gt;2.25.</li>\n<li>DPWG CYP2D6 ultrarapid metabolizer phenotype is assigned an AS of &gt;2.5.</li>\n</ul>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Guideline</th>\n<th>CNV Allele</th>\n<th>Function</th>\n<th>Activity<br/>value</th>\n<th>Other Allele<br/>Function</th>\n<th>Activity<br/>value</th>\n<th>CYP2D6 AS</th>\n<th>Phenotype</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>No function</td>\n<td>0</td>\n<td>2</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.25</td>\n<td>2.25</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Normal function</td>\n<td>1.0</td>\n<td>3.0</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x≥3</td>\n<td>Increased</td>\n<td>≥3</td>\n<td></td>\n<td></td>\n<td>≥3</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n</tbody>\n</table>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "xN combinations"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300964",
      "name": "Recommendation PA166300964",
      "population": "general",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451866",
          "name": "venlafaxine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093944,
        "html": "<p>No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.</p>\n"
      },
      "implications": [
        "CYP2D6: Decreased metabolism of venlafaxine to active metabolite O-desmethylvenlafaxine (desvenlafaxine) and decreased O-desmethylvenlafaxine:venlafaxine ratio as compared to normal metabolizers. There is insufficient evidence supporting the clinical impact of the decreased O-desmethylvenlafaxine:venlafaxine ratio in CYP2D6 intermediate metabolizers."
      ],
      "lookupKey": {
        "CYP2D6": "0.75"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300968",
      "name": "Recommendation PA166300968",
      "population": "general",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451866",
          "name": "venlafaxine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093948,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2D6: n/a"
      ],
      "lookupKey": {
        "CYP2D6": "n/a"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300955",
      "name": "Recommendation PA166300955",
      "population": "general",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451866",
          "name": "venlafaxine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093935,
        "html": "<p>No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.</p>\n"
      },
      "implications": [
        "CYP2D6: Increased metabolism of venlafaxine to the active metabolite O-desmethylvenlafaxine (desvenlafaxine) and increased O-desmethylvenlafaxine:venlafaxine ratio as compared to CYP2D6 normal metabolizers. There is insufficient evidence supporting the clinical impact of increased O-desmethylvenlafaxine:venlafaxine ratio in CYP2D6 ultrarapid metabolizers."
      ],
      "lookupKey": {
        "CYP2D6": "2.75"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300960",
      "name": "Recommendation PA166300960",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA451866",
          "name": "venlafaxine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093940,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n"
      },
      "implications": [
        "CYP2D6: Normal metabolism"
      ],
      "lookupKey": {
        "CYP2D6": "1.75"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300951",
      "name": "Recommendation PA166300951",
      "population": "general",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451866",
          "name": "venlafaxine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093931,
        "html": "<p>No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.</p>\n"
      },
      "implications": [
        "CYP2D6: Increased metabolism of venlafaxine to the active metabolite O-desmethylvenlafaxine (desvenlafaxine) and increased O-desmethylvenlafaxine:venlafaxine ratio as compared to CYP2D6 normal metabolizers. There is insufficient evidence supporting the clinical impact of increased O-desmethylvenlafaxine:venlafaxine ratio in CYP2D6 ultrarapid metabolizers."
      ],
      "lookupKey": {
        "CYP2D6": "≥5.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300957",
      "name": "Recommendation PA166300957",
      "population": "general",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451866",
          "name": "venlafaxine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093937,
        "html": "<p>No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.</p>\n"
      },
      "implications": [
        "CYP2D6: Increased metabolism of venlafaxine to the active metabolite O-desmethylvenlafaxine (desvenlafaxine) and increased O-desmethylvenlafaxine:venlafaxine ratio as compared to CYP2D6 normal metabolizers. There is insufficient evidence supporting the clinical impact of increased O-desmethylvenlafaxine:venlafaxine ratio in CYP2D6 ultrarapid metabolizers."
      ],
      "lookupKey": {
        "CYP2D6": "2.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300948",
      "name": "Recommendation PA166300948",
      "population": "general",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451866",
          "name": "venlafaxine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093928,
        "html": "<p>No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.</p>\n"
      },
      "implications": [
        "CYP2D6: Increased metabolism of venlafaxine to the active metabolite O-desmethylvenlafaxine (desvenlafaxine) and increased O-desmethylvenlafaxine:venlafaxine ratio as compared to CYP2D6 normal metabolizers. There is insufficient evidence supporting the clinical impact of increased O-desmethylvenlafaxine:venlafaxine ratio in CYP2D6 ultrarapid metabolizers."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300965",
      "name": "Recommendation PA166300965",
      "population": "general",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451866",
          "name": "venlafaxine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093945,
        "html": "<p>No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.</p>\n"
      },
      "implications": [
        "CYP2D6: Decreased metabolism of venlafaxine to active metabolite O-desmethylvenlafaxine (desvenlafaxine) and decreased O-desmethylvenlafaxine:venlafaxine ratio as compared to normal metabolizers. There is insufficient evidence supporting the clinical impact of the decreased O-desmethylvenlafaxine:venlafaxine ratio in CYP2D6 intermediate metabolizers."
      ],
      "lookupKey": {
        "CYP2D6": "0.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300952",
      "name": "Recommendation PA166300952",
      "population": "general",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451866",
          "name": "venlafaxine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093932,
        "html": "<p>No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.</p>\n"
      },
      "implications": [
        "CYP2D6: Increased metabolism of venlafaxine to the active metabolite O-desmethylvenlafaxine (desvenlafaxine) and increased O-desmethylvenlafaxine:venlafaxine ratio as compared to CYP2D6 normal metabolizers. There is insufficient evidence supporting the clinical impact of increased O-desmethylvenlafaxine:venlafaxine ratio in CYP2D6 ultrarapid metabolizers."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.75"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300956",
      "name": "Recommendation PA166300956",
      "population": "general",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451866",
          "name": "venlafaxine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093936,
        "html": "<p>No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.</p>\n"
      },
      "implications": [
        "CYP2D6: Increased metabolism of venlafaxine to the active metabolite O-desmethylvenlafaxine (desvenlafaxine) and increased O-desmethylvenlafaxine:venlafaxine ratio as compared to CYP2D6 normal metabolizers. There is insufficient evidence supporting the clinical impact of increased O-desmethylvenlafaxine:venlafaxine ratio in CYP2D6 ultrarapid metabolizers."
      ],
      "lookupKey": {
        "CYP2D6": "3.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300961",
      "name": "Recommendation PA166300961",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA451866",
          "name": "venlafaxine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093941,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n"
      },
      "implications": [
        "CYP2D6: Normal metabolism"
      ],
      "lookupKey": {
        "CYP2D6": "1.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": "37032427",
      "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.",
      "authors": [
        "Bousman Chad A",
        "Stevenson James M",
        "Ramsey Laura B",
        "Sangkuhl Katrin",
        "Hicks J Kevin",
        "Strawn Jeffrey R",
        "Singh Ajeet B",
        "Ruaño Gualberto",
        "Mueller Daniel J",
        "Tsermpini Evangelia Eirini",
        "Brown Jacob T",
        "Bell Gillian C",
        "Leeder J Steven",
        "Gaedigk Andrea",
        "Scott Stuart A",
        "Klein Teri E",
        "Caudle Kelly E",
        "Bishop Jeffrey R"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2023
    }
  ],
  "version": "2024-03-25-16-13"
}